PT  - JOURNAL ARTICLE
AU  - Wang, Xiaowei
AU  - Lagrange, JL
AU  - Zhang, Liangming
TI  - The Clinical Pathologic Analysis of Radiotherapy for Cutaneous B-cell Lymphoma
AID  - 10.1007/s11805-008-0040-4
DP  - 2008 Feb 01
TA  - Chinese Journal of Clinical Oncology
PG  - 40--43
VI  - 5
IP  - 1
4099  - http://www.cancerbiomed.org/content/5/1/40.short
4100  - http://www.cancerbiomed.org/content/5/1/40.full
SO  - Cancer Biol Med2008 Feb 01; 5
AB  - OBJECTIVE To report results of radiation therapy treatment of 30 B-cell lymphoma patients with an initial cutaneous presentation according to the new classification by the WHO/EORTC.METHODS Thirty patients with cutaneous B-cell lymphoma (CBCL) were treated by cutaneous irradiation based on the number and location of the lesions and the stage of their tumor. Treatment was conducted using a Saturne Clinac.RESULTS A complete response (CR) from the treatment for our series was 86%. The length of complete remission ranged from 4 to 301 months. Three patients (11%) developed a partial response (PR). One patient was progressive. Disease-free survival(DFS) at 10 years was 87%. Three patiens died [One PCMZL two PCLBCL leg type (29%)]. Radiotherapy was generally well tolerated.CONCLUSION According to the WHO/EORTC classification, the survivor results were good for PCMZL and PCFCL. The PCLBCL leg type had a poor prognosis. Localized field irradiation is an effective treatment for some localized forms of primary cutaneous B-cell lymphoma, and this mode of therapy can produce prolonged remissions. The patients with wide-spread skin involvement are usually candidates for extended field irradiation and/or chemotherapy. For advanced stages of cutaneous B-cell lymphoma, where chemotherapy is the treatment of choice, a degree of palliation can be achieved using local field irradation.